Skip to content

TARGET Registry A Project of the German Network for Intestinal Diseases in Cooperation With Other Corporate Partners

TARGET Registry A Project of the German Network for Intestinal Diseases in Cooperation With the German Association of Gastroenterologists in Private Practice (Bng) and Other Corporate Partners

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04031482
Acronym
TARGET
Enrollment
4400
Registered
2019-07-24
Start date
2019-10-31
Completion date
2023-09-30
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, Indeterminate Colitis, Ulcerative Colitis

Brief summary

By capturing possible or known risk factors, it will be possible to recognize connections between these risk factors and the disease, thus obtaining valuable insights into the cause of the disease. This in turn facilitates an improved evaluation of the treatment situation as well as influencing future framework conditions for preventive measures and planning treatments. Disease registries are thus crucial for the planning and structuring of health policies. The present registry protocol serves as a basis for the proper implementation of a registry for patients with chronic inflammatory bowel diseases. It describes the study rationale, objectives, design, participant groups, procedures and evaluation methods. Furthermore, it defines the responsibilities of each person involved in maintaining the registry and also forms the basis for decisions regarding evaluation by the Ethics Committee.

Detailed description

In view of the high prevalence and currently unsatisfactory treatment status, there is a significant medical demand for more effective treatment options. These require greater knowledge about the condition in the form of full disease progressions while exposed to a wide range of different treatment concepts and influencing factors. It has been possible to significantly increase scientific understanding of the pathogenesis of ulcerative colitis and Crohn's disease over the last few decades. Clinical and experimental results indicate a causal link with gastrointestinal barrier dysfunction and defective regulation of the immune system. However, no evidence has been found to prove that patients with the disease develop an immune deficiency by themselves, resulting in an increased susceptibility to bacterial or viral infections. Furthermore, there are unanswered questions concerning aetiology, risk factors and influencing factors for the early prediction of treatment responses. The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to * analyse disease progression * systematize findings about treatment processes * identify potential influencing factors * review any new diagnostic procedures * identify potential test subjects for further study * evaluate the safety of various treatment concepts A specific objective has not been defined for this registry as a registry does not per se need to build upon the foundation of a theoretically-deduced research hypothesis. Rather, it acts as a gateway for generating a systematic data repository. The registry offers researchers the opportunity to formulate their own research hypotheses based on the collected data and to then use the generated data pool to attempt to test their hypothesis. Additional data/variables could also be collected as necessary in order to answer certain questions.

Interventions

OTHERNo intervention, only standard care

The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to * analyse disease progression * systematize findings about treatment processes * identify potential influencing factors * review any new diagnostic procedures * identify potential test subjects for further study * evaluate the safety of various treatment concepts

Sponsors

Ced Service GmbH
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Confirmed diagnosis of Crohn's disease or Confirmed diagnosis of ulcerative colitis or Confirmed diagnosis of indeterminate colitis (IBDU) 2. All types of treatment commensurate with the medical practice, independent of any study 3. Age 18-80 4. Ongoing or incipient targeted therapies with biologics and/or other targeted therapies (e.g. Janus kinase inhibitors) 5. Sufficient ability to communicate in German language 6. Patient must be able to recognize the nature, significance and scope of this registry and to act accordingly 7. Computer/Tablet/mobile phone with internet access

Exclusion criteria

1. No declaration of consent is given 2. Age \< 18 and \> 80

Design outcomes

Primary

MeasureTime frameDescription
Disease activity3 Yearsharvey bradshaw index

Other

MeasureTime frameDescription
Quality of life (QOL)3 YearsThe Questioner EQ-5D is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D expresses the state of health of the respondents in a one-dimensional measure from 0 (very poor) to 1 (best possible state of health).
Use of glucocorticoids3 YearsUse of glucocorticoids
Need for surgery3 YearsNeed for surgery
Occurrence of side effects and infections3 YearsOccurrence of side effects and infections
Longevity of started treatments3 YearsLongevity of started treatments

Contacts

Primary ContactSonja Buske
s.buske@kompetenznetz-ced.de+49 4315929575371
Backup ContactSandra Plachta-Danielzik, PD Dr.
splachta-danielzik@kompetenznetz-ced.de+49 4315929575371

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026